 | 09/08/2010 08:30:21 AM
Medidata Solutions to Present at Key Events in September
Clinical Trial Technology Leaders to Share Expertise on Post-Approval Studies, Trial Budgeting and Clinical System Integrations.
[Business Wire] |
| 09/08/2010 08:30:01 AM
Opexa to Present at the Rodman & Renshaw 12th Annual Healthcare Conference on September 14, 2010
Opexa Therapeutics, Inc., a company developing Tovaxin®, a personalized T-cell immunotherapy for multiple sclerosis, today announced that Neil K. Warma, Opexa's President and Chief Executive Officer, will deliver a corporate presentation at the Rodman & Renshaw 12th Annual Healthcare Conference.
[Business Wire] |
| 09/08/2010 08:10:30 AM
SUNY Orange Foundation to Present Leadership Awards Sept. 21
The State University of New York-Orange County issued the following news release: A local medical center, a National Guard unit and a longtime professor will each be recognized for their contributions to the areas of business, community and education within the Hudson Valley when the SUNY Orange Foundation presents its annual Leadership Awards at 7 p.m., Tuesday, Sept. 21 in Orange Hall Theatre...
[Targeted News Service] |
| 09/08/2010 08:02:00 AM
INC Research to Present Value of Strategic Alliances for CROs and Sponsors in Exclusive Online Webinar Large Pharma Joins to Discuss Sponsor Benefits; Registration Open for Free Webinar on Sept. 15, 2010
09/08/10 -- INC Research ®, a therapeutically focused contract research organization with a trusted process for delivering reliable results, is hosting an upcoming thought-leading webinar on "The Value of Strategic Alliances vs.
[Market Wire] |
| 09/08/2010 08:00:30 AM
Cempra Pharmaceuticals Initiates Both a Phase 2 Study With an Oral Formulation and a Phase 1 Study of The Intravenous Formulation of Solithromycin (CEM-101), a Novel Fluoroketolide - Phase 2 Study of Oral Solithromycin Currently Enrolling Patients with Moderate-to-Moderately Severe Community-Acquired Bacterial Pneumonia- Solithromycin is the First member of the Macrolide Class Since Azithromycin with the Potential for Both Intravenous and Oral Administration
CHAPEL HILL, N.C., Sept. 8 Cempra Pharmaceuticals announced that it is moving forward in its dual approach to the development of solithromycin, a fluoroketolide which is first of a new generation of macrolide-ketolide antibiotics for treatment of community-acquired bacterial pneumonia.
[PR Newswire] |
| 09/08/2010 08:00:28 AM
Cylene to Report Recent Advances With First-in-Class CK2 Inhibitor, CX-4945, at International CK2 Conference Cylene's CX-4945 to be recognized as the only clinical stage CK2 inhibitor for multiple cancers
SAN DIEGO, Sept. 8 Cylene Pharmaceuticals, Inc. will report recent developments with its first-in-class, oral CK2 inhibitor CX-4945, at the 6th International Conference on Protein Kinase CK2, to be held on September 7-10 in Cologne, Germany, the company announced today.
[PR Newswire] |
| 09/08/2010 08:00:17 AM
Medicis Announces New Patent for SOLODYN(R)
Medicis today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,790,705 related to the use of SOLODYN® Extended Release Tablets.
[GlobeNewswire] |
| 09/08/2010 08:00:10 AM
Tetraphase to Present Extensive Data on Novel Broad Spectrum Antibiotic TP-434 at ICAAC
-Includes Oral Presentation and 12 posters- Tetraphase Pharmaceuticals, Inc., today announced that 12 poster presentations and an oral summary presentation on preclinical and clinical data for its lead drug candidate, TP-434, will be presented at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy in Boston, MA, being held September 12 -15 at the Boston Convention and Exhi...
[Business Wire] |
| 09/08/2010 08:00:08 AM
Progenics Pharmaceuticals Initiates Oral Methylnaltrexone Phase 3 Trial in Patients with Chronic Non-Cancer Pain
Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens.
[Business Wire] |
| 09/08/2010 08:00:04 AM
Rocking Out for a Vaccine: Styx Founder Chuck Panozzo Joins the Battle Against HIV
09/08/10 -- Chuck Panozzo has lived a rock star's life. Panozzo has joined forces with Atlanta-based biotech firm GeoVax Labs as a spokesperson for the company's HIV/AIDS vaccines, currently in clinical trials. Panozzo commented, "I was sincerely touched by [Robinson's] success and determination in her pursuit to bring an end to the devastating AIDS pandemic.
[Market Wire] |
| 09/08/2010 08:00:00 AM
Rexahn Pharmaceuticals to Present at the Rodman & Renshaw 12th Annual Healthcare Conference
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it will present at the Rodman & Renshaw 12th Annual Healthcare Conference on September 14, 2010, at 11:15 a.m. Eastern Time at the New York Palace Hotel in New York, NY. Rexahn's President and Chief Operating Officer, Ri...
[Business Wire] |
| 09/08/2010 07:36:05 AM
YM BioSciences announces positive results from CYT997 Phase I Study (YMI)
YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent, was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors.
[Benzinga] |
| 09/08/2010 07:30:28 AM
YM BioSciences announces positive results from CYT997 Phase I study published in British Journal of Cancer
-CYT997 well tolerated at doses associated with vascular disruption in tumors- YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent, was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors.
[Canada Newswire] |
| 09/08/2010 07:30:26 AM
YM BioSciences announces positive results from CYT997 Phase I study published in British Journal of Cancer
-CYT997 well tolerated at doses associated with vascular disruption in tumors- MISSISSAUGA, ON, Sept. 8 YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent, was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors.
[PR Newswire] |
| 09/08/2010 07:30:04 AM
Enobia Provides Update on Progress With ENB-0040, a Bone-Targeted Enzyme Replacement Therapy for Hypophosphatasia -- Key Composition of Matter Patent Issued for Investigational Treatment ---- Phase 2 Data to be Presented at Upcoming Scientific Meetings --
MONTREAL, Sept. 8 Enobia Pharma today provided an update on key developments in its comprehensive effort to develop ENB-0040, an experimental bone-targeted enzyme replacement therapy, for the treatment of hypophosphatasia. Enobia announced today that it has been issued United States Patent No. 7,763,712 B2, providing robust intellectual property coverage for targeting alkaline phosphatase to bone.
[PR Newswire] |
| |
previous
|
next |
|
